Innovation That Matters: The Latest from WXPRESS

New Milestones in Strengthening WuXi AppTec CRDMO Platform to Better Support Customers

This summer, we continue to strengthen our unique Contract Research, Development and Manufacturing Organization (CRDMO) platform with the expansion of our Munich site on July 24, following the groundbreaking of our new site in Singapore on May 23. The Munich site consolidates structure-based drug discovery and lab testing capabilities under one roof, enhancing services for customers in Europe and beyond. Meanwhile, the 50-acre Singapore site will house seven plants offering R&D and manufacturing services for APIs, small molecules, oligonucleotides, peptides, and complex synthetic conjugates. Both sites will integrate closely with our existing global network in Asia, Europe and North America to better support our global customers to deliver groundbreaking therapies to patients worldwide.  

How Research & Education Can Impact an Aging Society: A Singapore Perspective

As we celebrate the groundbreaking of our Singapore site, we're revisiting a fascinating interview we conducted two years ago on healthy aging with Dr. Benjamin Seet, Group Chairman Medical Board (Research) at the National Healthcare Group in Singapore that serves about 30% of the nation’s population. Back then, we were just announcing plans for our new facility in Singapore. Today, the insights shared in that interview are more relevant than ever as we continue to expand our capabilities to serve the local innovation community and our global customers dedicated to a healthy future for all. Read more►

BOLD - Innovation That Matters

BOLD, in our spirit, stands for Breaking Barriers, Opening New Horizons, Leading the Next Generation, and Delivering on the Promise for Patients. As we continue this interview series, we spotlight on cancer in this edition, and highlight fresh perspectives from several emerging companies on their bold approaches and progresses across a spectrum of modalities including next generation small molecule, radiopharmaceuticals, and cellular medicine.

Emanuele Ostuni, CEO, ARTBIO. ARTBIO strives to redefine cancer care by creating a new class of alpha radioligand therapies. ARTBIO is shaped by a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy conducted at the University of Oslo and Norway’s Radium Hospital.

Shengfang Jin, President & CEO, Ensem Therapeutics. Ensem Therapeutics is developing innovative small molecule precision medicines for oncology by integrating computational and AI deep learning to identify non-obvious binding pockets, with a focus on high-value and difficult-to-drug targets.

Peretz Partensky, Co-Founder & CEO, ImmuneBridge. ImmuneBridge is developing the next generation of allogeneic cellular medicines, starting with NK cell-based immunotherapies. Its proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency—to create a consistent and abundant cellular source for immunotherapies.

Manfred Rüdiger, CEO, Ariceum Therapeutics. Ariceum Therapeutics is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of ‘Marie Curie’ whose discovery of radium and polonium have been huge contributions to finding treatments for cancer.

World Lung Cancer Day: Celebrating Breakthroughs in Lung Cancer Treatment



August 1st marks World Lung Cancer Day—a day dedicated to raising awareness, reflecting on progress, and envisioning a future where lung cancer is no longer a leading cause of death. This year's theme, "Stronger Together," resonates deeply with WuXi AppTec. It’s a reminder of the incredible strides our industry has made in developing new treatments that offer hope to patients worldwide. Read more►